Subscribe To

Price Alert Latest News Economic Calendar News

TNXP / Tonix Says Fibromyalgia Candidate Failed To Achieve Statistical Significance Over Placebo

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) says that as expected, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) did not significantly reduce fibromyalgia daily pain at Week 14 compared to placebo in the Phase 3 RALLY study. Tonix reported interim analysis. Read More

Demo Live Account See Partner Details

Content Topics

Tonix

Says

Fibromyalgia

Candidate

Failed

Achieve

Statistical

Significance

Placebo

Stock

TNXP

Posted: Mar 21 2022, 10:20

Author Name: Benzinga

TNXP News

By Market Watch
October 31, 2023

Tonix shares sink 29% on discontinued development on depression treatment

Shares of Tonix Pharmaceuticals TNXP fell Tuesday after the company said it would discontinue development of its treatment for major depressive disord

By InvestorPlace
September 29, 2023

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 29% Today?

Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling hard on Friday after the clinical-stage biopharmaceutical company priced a share offering. Acc

By GlobeNewsWire
August 17, 2023

Tonix Pharmaceuticals to Present at the August Virtual Investor Summit

CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed product

By InvestorPlace
July 28, 2023

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 43% Today?

Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is taking a beating on Friday after the company announced a public stock offering. That public stock offe

By Proactive Investors
March 23, 2023

Tonix Pharmaceuticals exec presents data on Prader-Willi Syndrome drug at rare disease conference

Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp EVP of translation medicine Herbert Harris delivered an oral presentation Thursday at the Rare Diseas

By Proactive Investors
February 13, 2023

Tonix Pharmaceuticals obtains exclusive license to develop fully human and murine anti-SARS-CoV-2 monoclonal antibodies

Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp. said it has exercised an option to obtain an exclusive license from Columbia University for the deve

By PennyStocks
January 9, 2023

Using News to Find Penny Stocks to Buy: 3 Tips

Are you using the news to find penny stocks to buy? The post Using News to Find Penny Stocks to Buy: 3 Tips appeared first on Penny Stocks to Buy, Pic

By InvestorPlace
December 12, 2022

Why Is Tonix Pharmaceuticals (TNXP) Stock Up 40% Today?

Today is a banner day for anyone who happened to hold Tonix Pharmaceuticals (NASDAQ: TNXP ) stock over the weekend. Early this morning, Tonix disclose

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.